| |
MESOTHELIOMA NEWS
MesotheliomaHelp.net
is focused on providing information about
mesothelioma to those victims and their families stricken by asbestos.
The following online mesothelioma library
provides immediate access to detailed medical and legal information. We have
featured some articles, that provide significant information, as 'must reads'.
02/05/2004
FDA Approves First Drug for Rare Type of
Cancer
The Food and Drug Administration (FDA) today approved Alimta (pemetrexed
disodium) for use in combination with cisplatin for the treatment of patients
with malignant pleural mesothelioma-a rare type of cancer. Alimta received a
priority review and is designated as an orphan drug. It is the first drug
approved for this condition.
Cancer of the mesothelium, a membrane that covers and protects most of the
internal organs of the body is rare; about 2,000 new cases are diagnosed in the
United States each year. This form of cancer is usually associated with a
history of asbestos exposure. Asbestos fibers lodged in the lung attach to the
outer lung lining and chest wall, causing tumors to grow. By the time symptoms
appear, the disease is usually advanced, and patients live, on average, nine to
thirteen months following diagnosis.
> Read full FDA release
02/2004
Study Supports Development Potential in Several Therapeutic Areas
The study, titled, "Autocrine inhibitory influences of
alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma," might provide a novel strategy to reduce
mesothelioma cell proliferation.
> Read Full News Article
> Read Abstract
for New Study
11/2003
Pacific Northwest Research Institute reported the
development of a blood test for mesothelioma.
Seattle-Researchers at the Pacific Northwest Research Institute (PNRI) have
reported the development of a blood test for mesothelioma, a highly aggressive
lung cancer caused by asbestos exposure.
A PNRI team led by Dr. Ingegerd Hellstrom, and an Australian team, led by Dr.
Bruce Robinson, of the University of Western Australia, conducted the research,
which appears in the November 15th issue of Lancet. The new test promises a
simple technique for diagnosing and monitoring mesothelioma early in its
progress, when therapy is more likely to be successful. Fujirebio Diagnostics,
Inc. (FDI) of Malvern, PA, a leading oncology diagnostic company, has acquired
an exclusive license from PNRI to develop a commercial test for worldwide
distribution.
> Read Full News Article
|
|
|
 |
| |
To request a free case
evaluation, please complete
the following: |
|
|
|
|
|
